TD Cowen Cuts Soleno Therapeutics (NASDAQ:SLNO) Price Target to $85.00

Soleno Therapeutics (NASDAQ:SLNO) had its target price lowered by TD Cowen from $120.00 to $85.00 in a research report report published on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

SLNO has been the topic of several other reports. Robert W. Baird set a $107.00 price target on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. HC Wainwright restated a “buy” rating and set a $120.00 target price (up from $110.00) on shares of Soleno Therapeutics in a report on Tuesday, January 20th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $114.00 price target (up from $106.00) on shares of Soleno Therapeutics in a report on Tuesday, January 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Finally, Wolfe Research set a $60.00 target price on Soleno Therapeutics in a report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Soleno Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $108.38.

Soleno Therapeutics Trading Up 2.6%

Shares of NASDAQ:SLNO opened at $39.07 on Thursday. The company has a 50 day moving average of $42.63 and a 200-day moving average of $53.33. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10. The firm has a market cap of $2.02 billion, a P/E ratio of 169.88 and a beta of -3.16. Soleno Therapeutics has a twelve month low of $32.63 and a twelve month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. As a group, analysts anticipate that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Soleno Therapeutics

A number of large investors have recently made changes to their positions in the business. Raymond James Financial Inc. purchased a new position in Soleno Therapeutics during the second quarter valued at approximately $25,000. Danske Bank A S acquired a new position in shares of Soleno Therapeutics in the third quarter worth $27,000. Global Retirement Partners LLC raised its holdings in shares of Soleno Therapeutics by 519.0% during the fourth quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock worth $29,000 after acquiring an additional 519 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in Soleno Therapeutics in the third quarter valued at about $37,000. Finally, Nisa Investment Advisors LLC increased its position in Soleno Therapeutics by 287.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after purchasing an additional 400 shares during the last quarter. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics News Roundup

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Earnings beat and profitability: Soleno reported Q4 2025 EPS of $0.80 (vs. $0.64 consensus) and revenue of $91.73M (vs. $88.55M), and management highlighted achieving profitability — the core reason investors are bidding the stock up. Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Full earnings/transcript availability: Multiple transcripts and call write-ups (Seeking Alpha, Yahoo) give investors detailed color on guidance, margins and cash flow — useful for conviction but not immediate catalysts. Q4 2025 Earnings Call Transcript Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Wells Fargo cut its price target slightly from $114 to $110 but kept an Overweight rating — this is a modest headwind but still signals strong upside from analysts. Wells Fargo price-target note
• Negative Sentiment: TD Cowen substantially lowered its target (from $120 to $85) despite maintaining a Buy rating — the larger cut adds downward pressure to headline analyst sentiment and may temper the rally. TD Cowen price-target change
• Negative Sentiment: Near-term volatility / profit-taking explained: Coverage and commentary note a sharp intraday decline (reported as ~10.8% in one write-up) after the earnings run-up — investors appear to be re‑rating the name on guidance details, forward EPS expectations, and valuation. Why SLNO Stock Is Down 10.80%

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.